Background Selpercatinib is a highly selective and potent, brain penetrant RET inhibitor,
approved for treatment of advanced RET fusion-positive (RET+) NSCLC. Selpercatinib had …

Background Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung …

3094 Background: Selpercatinib, a first-in-class highly selective and potent RET kinase
inhibitor, is approved in multiple countries for the treatment of lung and thyroid cancer with …

PURPOSE Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase
inhibitor, is currently approved for the treatment of patients with RET fusion–positive non …

Background Selpercatinib, a first-in-class highly selective and potent CNS-active RET
kinase inhibitor, is approved in multiple countries for treatment of RET fusion+ NSCLC. In …

Introduction Central nervous system (CNS) metastases develop in nearly half of patients
with RET fusion-positive NSCLCs and cause morbidity and mortality. The selective RET …

9065 Background: Selpercatinib, a first-in-class highly selective and potent, CNS-active RET
kinase inhibitor, is approved in multiple countries for treatment of RET fusion+ lung or thyroid …

Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in
non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have …

PURPOSE Selpercatinib, a highly selective, potent RET inhibitor with CNS activity,
demonstrated sustained antitumor responses and intracranial activity in patients with RET …

Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …